12-hydroxy steroid - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	12-hydroxy steroid	go back to main search page
Accession:	CHEBI:36845	browse the term
Synonyms:	related_synonym:	12-hydroxy steroids

show annotations for term's descendants Sort by:
Rat (538) Mouse (547) Human (549) Chinchilla (0) Bonobo (0) Dog (1) Squirrel (0) Pig (6) Green Monkey (0) Naked Mole-rat (0) All
Genes (538)

(20R)-protopanaxadiol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

protopanaxadiol inhibits the reaction [Scopolamine results in increased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

Bcl2-like 1

increases expression

protopanaxadiol results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

baculoviral IAP repeat-containing 5

affects expression

protopanaxadiol affects the expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

caspase 3

increases expression
affects cleavage

protopanaxadiol results in increased expression of CASP3 mRNA
protopanaxadiol affects the cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases expression
affects expression

protopanaxadiol results in increased expression of CASP9 mRNA
protopanaxadiol affects the expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin A2

increases expression

protopanaxadiol results in increased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:119,426,089...119,433,577

G

cyclin B1

increases expression

protopanaxadiol results in increased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin D1

increases expression

protopanaxadiol results in increased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cell division cycle 25A

multiple interactions
increases expression

protopanaxadiol results in increased expression of and results in decreased phosphorylation of CDC25A protein
protopanaxadiol results in increased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

increases expression
multiple interactions

protopanaxadiol results in increased expression of CDC25C mRNA
protopanaxadiol affects the expression of and affects the phosphorylation of CDC25C protein

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cyclin-dependent kinase 1

increases expression

protopanaxadiol results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin dependent kinase 2

increases expression

protopanaxadiol results in increased expression of CDK2 mRNA

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

increases expression

protopanaxadiol results in increased expression of CDK4 mRNA; protopanaxadiol results in increased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

choline O-acetyltransferase

multiple interactions

protopanaxadiol inhibits the reaction [Scopolamine results in decreased activity of CHAT protein]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

epidermal growth factor receptor

multiple interactions
decreases activity

protopanaxadiol results in decreased expression of and results in increased phosphorylation of EGFR protein
protopanaxadiol results in decreased activity of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

early growth response 1

multiple interactions

protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of EGR1 protein]

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of FOS protein]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

protopanaxadiol inhibits the reaction [Scopolamine results in decreased expression of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

mitogen activated protein kinase kinase 1

increases expression

protopanaxadiol results in increased expression of MAP2K1 mRNA

NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147

G

mitogen activated protein kinase 1

decreases phosphorylation

protopanaxadiol results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation

protopanaxadiol results in decreased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

poly (ADP-ribose) polymerase 1

increases expression

protopanaxadiol results in increased expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

Raf-1 proto-oncogene, serine/threonine kinase

increases phosphorylation

protopanaxadiol results in increased phosphorylation of RAF1 protein

NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317

G

ribosomal protein S6 kinase A1

increases expression

protopanaxadiol results in increased expression of RPS6KA1 mRNA

NCBI chr 5:146,079,018...146,118,272
Ensembl chr 5:146,079,021...146,118,272

G

signal transducer and activator of transcription 3

affects expression

protopanaxadiol affects the expression of STAT3 protein

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

tumor protein p53

increases expression

protopanaxadiol results in increased expression of TP53 mRNA; protopanaxadiol results in increased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

(20S)-ginsenoside Rg3

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily G member 2

multiple interactions
decreases expression

XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of ABCG2 mRNA]

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acid phosphatase 5, tartrate resistant

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased activity of ACP5 protein]

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929

G

androgen receptor

increases degradation
multiple interactions

ginsenoside Rg3 results in increased degradation of AR protein
ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of AR protein]

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

amphiregulin

decreases expression

ginsenoside Rg3 results in decreased expression of AREG mRNA

NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535

G

BCL2 associated X, apoptosis regulator

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

brain-derived neurotrophic factor

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]

NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615

G

beclin 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in decreased expression of BECN1 protein]

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone gamma-carboxyglutamate protein

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BGLAP protein]

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

baculoviral IAP repeat-containing 5

decreases expression

ginsenoside Rg3 results in decreased expression of BIRC5 mRNA; ginsenoside Rg3 results in decreased expression of BIRC5 protein

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

bone morphogenetic protein 2

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMP2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

bone morphogenetic protein receptor type 1A

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of BMPR1A protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]

NCBI chr16:9,736,390...9,829,825
Ensembl chr16:9,736,630...9,780,616

G

caspase 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

increases cleavage
multiple interactions

ginsenoside Rg3 results in increased cleavage of CASP3 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of CASP3 protein; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP3 protein]

PMID:22101440 PMID:26427350 PMID:31916386

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP8 protein]

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of CASP9 protein]

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

ginsenoside Rg3 inhibits the reaction [dimethoxon results in decreased activity of CAT protein]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cellular communication network factor 1

decreases expression

ginsenoside Rg3 results in decreased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 2

decreases expression

ginsenoside Rg3 results in decreased expression of CCN2 mRNA

NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734

G

cadherin 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

dipeptidylpeptidase 4

multiple interactions

[Xiao-Ke-An results in increased abundance of ginsenoside Rg3] which results in decreased activity of DPP4 protein

NCBI chr 3:46,962,233...47,043,870
Ensembl chr 3:46,962,243...47,043,901

G

epidermal growth factor

multiple interactions

EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

multiple interactions
affects phosphorylation

EGF protein promotes the reaction [ginsenoside Rg3 affects the phosphorylation of EGFR protein]; ginsenoside Rg3 inhibits the reaction [EGF protein promotes the reaction [EGFR protein binds to EGFR protein]]; ginsenoside Rg3 results in decreased expression of and affects the localization of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

epithelial cell adhesion molecule

decreases expression

ginsenoside Rg3 results in decreased expression of EPCAM mRNA

NCBI chr 6:6,880,142...6,896,103
Ensembl chr 6:6,878,237...6,896,127

G

fucosyltransferase 4

multiple interactions
decreases expression

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of FUT4 protein]
ginsenoside Rg3 results in decreased expression of FUT4 protein

NCBI chr 8:11,586,721...11,590,682
Ensembl chr 8:11,586,721...11,590,682

G

heat shock transcription factor 1

multiple interactions
decreases expression

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in increased expression of HSF1 protein]
ginsenoside Rg3 results in decreased expression of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

interleukin 1 beta

increases expression
multiple interactions

ginsenoside Rg3 results in increased expression of IL1B protein
ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of IL1B protein]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of IL1B protein]

PMID:14534150 PMID:33050067 PMID:34423507

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Rg3 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

KIT proto-oncogene receptor tyrosine kinase

decreases expression

ginsenoside Rg3 results in decreased expression of KIT mRNA

NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652

G

KLF transcription factor 4

decreases expression

ginsenoside Rg3 results in decreased expression of KLF4 mRNA

NCBI chr 5:70,278,843...70,283,751
Ensembl chr 5:70,278,972...70,283,602

G

kallikrein 1-related peptidase C10

multiple interactions

ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 mRNA]; ginsenoside Rg3 inhibits the reaction [Testosterone results in increased expression of KLK3 protein]

NCBI chr 1:94,402,993...94,407,052
Ensembl chr 1:94,402,993...94,407,052

G

large tumor suppressor kinase 1

increases expression

ginsenoside Rg3 results in increased expression of LATS1 mRNA

NCBI chr 1:2,160,411...2,193,640
Ensembl chr 1:2,160,411...2,193,640

G

large tumor suppressor kinase 2

increases expression

ginsenoside Rg3 results in increased expression of LATS2 mRNA

NCBI chr15:31,825,068...31,877,193
Ensembl chr15:31,825,092...31,877,220

G

microtubule-associated protein 2

increases expression

ginsenoside Rg3 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

marker of proliferation Ki-67

multiple interactions

[ginsenoside Rg3 co-treated with osimertinib] results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 2

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

myeloperoxidase

multiple interactions

ginsenoside Rg3 inhibits the reaction [dimethoxon results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

MYC proto-oncogene, bHLH transcription factor

decreases expression

ginsenoside Rg3 results in decreased expression of MYC mRNA

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

Nanog homeobox

decreases expression

ginsenoside Rg3 results in decreased expression of NANOG mRNA

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:155,943,737...155,951,116

G

nuclear factor kappa B subunit 1

multiple interactions
increases activity

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein
ginsenoside Rg3 results in increased activity of NFKB1 protein

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of NFKB1 protein; [ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NLR family, pyrin domain containing 3

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

noggin

multiple interactions

NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMP2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of BMPR1A protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]

NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339

G

nitric oxide synthase 2

multiple interactions
increases expression

Staurosporine inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [ginsenoside Rg3 results in increased expression of NOS2 protein]
ginsenoside Rg3 results in increased expression of NOS2 mRNA

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurotrophic receptor tyrosine kinase 2

multiple interactions

[staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of BDNF protein]]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]
[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of NTRK2 protein modified form]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] inhibits the reaction [[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] results in decreased susceptibility to Chlorodiphenyl (54% Chlorine)]; [staurosporine aglycone binds to and results in decreased activity of NTRK2 protein] results in decreased susceptibility to [Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3]

NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

ginsenoside Rg3 results in increased cleavage of PARP1 protein
[ginsenoside Rg3 co-treated with osimertinib] results in increased cleavage of PARP1 protein; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased cleavage of PARP1 protein]

PMID:22101440 PMID:24793912 PMID:26427350 PMID:31916386

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

increases expression

ginsenoside Rg3 results in increased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

POU class 5 homeobox 1

decreases expression

ginsenoside Rg3 results in decreased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,223,129...3,227,891

G

PPARG coactivator 1 alpha

increases expression

ginsenoside Rg3 results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

prominin 1

decreases expression
multiple interactions

ginsenoside Rg3 results in decreased expression of PROM1 mRNA
XMU-MP-1 inhibits the reaction [ginsenoside Rg3 results in decreased expression of PROM1 mRNA]

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

PYD and CARD domain containing

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]
3-methyladenine inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]]; ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of PYCARD protein]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

[ginsenoside Rg3 results in increased phosphorylation of and results in increased degradation of NFKBIA protein] which results in increased activity of RELA protein; ginsenoside Rg3 affects the localization of and results in increased activity of RELA protein
ginsenoside Rg3 results in decreased expression of and results in decreased phosphorylation of RELA protein

PMID:14534150 PMID:33050067

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of RUNX2 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone inhibits the reaction [[Ascorbic Acid co-treated with beta-glycerophosphoric acid] results in increased expression of RUNX2 protein]]]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

spalt-like transcription factor 4

decreases expression

ginsenoside Rg3 results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

sirtuin 1

increases activity

ginsenoside Rg3 results in increased activity of SIRT1 protein

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 6 member 2

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A2 protein]

NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357

G

solute carrier family 6 member 3

multiple interactions

[Plant Extracts co-treated with Terpenes co-treated with ginsenoside Rg3] inhibits the reaction [Chlorodiphenyl (54% Chlorine) results in decreased expression of SLC6A3 protein]

NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413

G

SMAD family member 2

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

snail family transcriptional repressor 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]

NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969

G

SRY-box transcription factor 2

decreases expression

ginsenoside Rg3 results in decreased expression of SOX2 mRNA

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

Sp1 transcription factor

multiple interactions

ginsenoside Rg3 inhibits the reaction [cagA protein, Helicobacter pylori results in decreased expression of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

sequestosome 1

multiple interactions

ginsenoside Rg3 inhibits the reaction [Cisplatin results in increased expression of SQSTM1 protein]
3-methyladenine affects the reaction [ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]]; ginsenoside Rg3 affects the reaction [Cisplatin affects the expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine/threonine kinase 3

increases expression

ginsenoside Rg3 results in increased expression of STK3 mRNA

NCBI chr 7:66,053,209...66,323,292
Ensembl chr 7:66,052,345...66,323,233

G

serine/threonine kinase 4

increases expression

ginsenoside Rg3 results in increased expression of STK4 mRNA

NCBI chr 3:152,745,958...152,827,747
Ensembl chr 3:152,745,681...152,827,744

G

transforming growth factor, beta 1

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in decreased expression of CDH1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased cleavage of PARP1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of and results in increased activity of MMP2 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of MMP2 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 mRNA]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of SNAI1 protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]; ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased phosphorylation of SMAD2 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

Thy-1 cell surface antigen

decreases expression

ginsenoside Rg3 results in decreased expression of THY1 mRNA

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

increases expression
multiple interactions

ginsenoside Rg3 results in increased expression of TNF protein
ginsenoside Rg3 inhibits the reaction [dimethoxon results in increased expression of TNF protein]
ginsenoside Rg3 inhibits the reaction [[Lipopolysaccharides co-treated with Adenosine Triphosphate] results in increased secretion of TNF protein]; ginsenoside Rg3 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]

PMID:14534150 PMID:26240163 PMID:33050067

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF receptor superfamily member 11B

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in decreased expression of TNFRSF11B protein]]

NCBI chr 7:85,566,520...85,594,526
Ensembl chr 7:85,566,520...85,594,538

G

TNF superfamily member 11

multiple interactions

ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]; ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 mRNA]]; NOG protein inhibits the reaction [ginsenoside Rg3 inhibits the reaction [Dexamethasone results in increased expression of TNFSF11 protein]]

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

G

vimentin

multiple interactions

ginsenoside Rg3 analog inhibits the reaction [TGFB1 protein results in increased expression of VIM protein]

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

G

WW domain containing transcription regulator 1

decreases expression

ginsenoside Rg3 results in decreased expression of WWTR1 mRNA

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:141,648,108...141,766,968

G

Yes1 associated transcriptional regulator

decreases expression

ginsenoside Rg3 results in decreased expression of YAP1 mRNA

NCBI chr 8:5,095,705...5,166,808
Ensembl chr 8:5,095,722...5,167,010

(20S)-ginsenoside Rh1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ginsenoside Rh1 results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

intercellular adhesion molecule 1

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interleukin 1 beta

multiple interactions

ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

decreases expression

ginsenoside Rh1 results in decreased expression of IL4

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

ginsenoside Rh1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha 4

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]

NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715

G

integrin subunit alpha L

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit beta 1

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 2

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

Jun proto-oncogene, AP-1 transcription factor subunit

decreases activity

ginsenoside Rh1 results in decreased activity of JUN protein

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

lipoprotein lipase

increases secretion

ginsenoside Rh1 results in increased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

progesterone receptor

increases expression

ginsenoside Rh1 results in increased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

peroxisome proliferator-activated receptor gamma

multiple interactions

ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA]; ginsenoside Rh1 inhibits the reaction [bisphenol A results in increased expression of PPARG protein]

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

selectin E

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

trefoil factor 1

increases expression

ginsenoside Rh1 results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tumor necrosis factor

multiple interactions
decreases expression
decreases response to substance

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]
ginsenoside Rh1 inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Rh1 inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]
ginsenoside Rh1 results in decreased expression of TNF
ginsenoside Rh1 results in decreased susceptibility to TNF protein

PMID:16557482 PMID:21875580 PMID:22855946

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

ginsenoside Rh1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

(20S)-ginsenoside Rh2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

decreases phosphorylation

ginsenoside Rh2 results in decreased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

increases expression

ginsenoside Rh2 results in increased expression of BAX protein

PMID:26482938 PMID:32762018

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

ginsenoside Rh2 results in decreased expression of BCL2 protein

PMID:26482938 PMID:32762018

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

increases cleavage
decreases expression

ginsenoside Rh2 results in increased cleavage of CASP3 protein
ginsenoside Rh2 results in decreased expression of CASP3 protein

PMID:26482938 PMID:32762018

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

decreases expression

ginsenoside Rh2 results in decreased expression of CASP9 protein

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

cyclin D1

decreases expression

ginsenoside Rh2 results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

histone deacetylase 1

decreases expression

ginsenoside Rh2 results in decreased expression of HDAC1 protein

NCBI chr 5:141,853,992...141,881,057
Ensembl chr 5:141,853,989...141,881,111

G

histone deacetylase 2

decreases expression

ginsenoside Rh2 results in decreased expression of HDAC2 protein

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 6

decreases expression

ginsenoside Rh2 results in decreased expression of HDAC6 protein

NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441

G

interleukin 6

multiple interactions

ginsenoside Rh2 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

mitogen activated protein kinase 1

decreases phosphorylation
increases phosphorylation

ginsenoside Rh2 results in decreased phosphorylation of MAPK1 protein
ginsenoside Rh2 results in increased phosphorylation of MAPK1 protein

PMID:26482938 PMID:32762018

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
increases phosphorylation

ginsenoside Rh2 results in decreased phosphorylation of MAPK3 protein
ginsenoside Rh2 results in increased phosphorylation of MAPK3 protein

PMID:26482938 PMID:32762018

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mechanistic target of rapamycin kinase

decreases phosphorylation

ginsenoside Rh2 results in decreased phosphorylation of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFKB inhibitor alpha

increases expression

ginsenoside Rh2 results in increased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside Rh2 results in increased expression of and results in decreased phosphorylation of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

cholic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression
multiple interactions

Cholic Acid results in increased expression of ABCA1 mRNA
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCA1 mRNA

PMID:14684380 PMID:15694933

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 8

multiple interactions

[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA

NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988

G

ATP binding cassette subfamily A member 9

multiple interactions

[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA

NCBI chr10:95,077,615...95,137,751
Ensembl chr10:95,079,058...95,139,608

G

ATP binding cassette subfamily B member 11

increases expression
decreases activity
multiple interactions

Cholic Acid results in increased expression of ABCB11 mRNA
Cholic Acid results in increased expression of ABCB11 mRNA; Cholic Acid results in increased expression of ABCB11 protein
Cholic Acid results in decreased activity of ABCB11 protein
Cholic Acid inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB11 mRNA]
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ABCB11 mRNA

PMID:11438506 PMID:12971955 PMID:14684380 PMID:15466244 PMID:15694933 More...

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression

Cholic Acid results in increased expression of ABCB1A mRNA; Cholic Acid results in increased expression of ABCB1A protein

PMID:11438506 PMID:17521389

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases expression

Cholic Acid results in increased expression of ABCB1B mRNA; Cholic Acid results in increased expression of ABCB1B protein

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

ATP binding cassette subfamily B member 4

affects secretion
increases expression
multiple interactions

ABCB4 affects the secretion of Cholic Acid
Cholic Acid results in increased expression of ABCB4 mRNA
epiallopregnanolone sulfate inhibits the reaction [Cholic Acid results in increased expression of ABCB4 mRNA]

PMID:12967592 PMID:22961653 PMID:25582706

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

multiple interactions

Cholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases expression

Cholic Acid results in increased expression of ABCC2 mRNA
Cholic Acid results in increased expression of ABCC2 mRNA; Cholic Acid results in increased expression of ABCC2 protein

PMID:11438506 PMID:12971955 PMID:15694933 PMID:25055961 PMID:25582706

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Cholic Acid results in increased expression of ABCC3 mRNA

PMID:12971955 PMID:25055961 PMID:25582706

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily G member 1

multiple interactions

[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 5

increases expression
multiple interactions

Cholic Acid results in increased expression of ABCG5 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA

PMID:25055961 PMID:25582706 PMID:30996006

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

increases expression
multiple interactions

Cholic Acid results in increased expression of ABCG8 mRNA
[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA

PMID:25582706 PMID:30996006

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acetyl-CoA carboxylase alpha

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACACA mRNA]

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

acyl-CoA oxidase 1

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of ACSL1 mRNA]

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

actin alpha 2, smooth muscle

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

aryl hydrocarbon receptor

multiple interactions
increases secretion
increases abundance

AHR gene mutant form inhibits the reaction [Tetrachlorodibenzodioxin results in decreased secretion of Cholic Acid]
AHR gene mutant form results in increased secretion of Cholic Acid
AHR gene mutant form results in increased abundance of Cholic Acid

PMID:29452137 PMID:32679164

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1 member C3-like 1

increases abundance

AKR1C4 protein results in increased abundance of Cholic Acid

NCBI chr17:65,847,580...65,881,488
Ensembl chr17:65,835,634...65,881,488

G

AKT serine/threonine kinase 1

multiple interactions

Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein; Diethylnitrosamine inhibits the reaction [Cholic Acid results in increased activity of and results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

ATPase phospholipid transporting 8B1

multiple interactions

[NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

caspase 3

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased cleavage of CASP3 protein]; Cholic Acid inhibits the reaction [Diethylnitrosamine results in increased cleavage of CASP3 protein]

PMID:27151938 PMID:35622622

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein; lupeol inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; lupeol linoleate inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased activity of CAT protein]; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CAT protein]

PMID:16933029 PMID:33845646

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin D1

multiple interactions
increases expression

[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of CCND1 protein
Cholic Acid results in increased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CD36 molecule

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of CD36 protein]

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase inhibitor 1A

decreases expression
multiple interactions

Cholic Acid results in decreased expression of CDKN1A protein
[Diethylnitrosamine co-treated with Cholic Acid] results in decreased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

checkpoint kinase 1

increases expression

Cholic Acid results in increased expression of CHEK1 protein

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

cholinergic receptor, muscarinic 2

increases expression

Cholic Acid results in increased expression of CHRM2 mRNA

NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103

G

claudin 1

decreases expression

Cholic Acid results in decreased expression of CLDN1 mRNA; Cholic Acid results in decreased expression of CLDN1 protein

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 2

decreases expression

Cholic Acid results in decreased expression of CLDN2 mRNA; Cholic Acid results in decreased expression of CLDN2 protein

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

carnitine palmitoyltransferase 1A

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CPT1A mRNA]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cytochrome P450, family 27, subfamily a, polypeptide 1

decreases expression

Cholic Acid results in decreased expression of CYP27A1 mRNA

PMID:7832767 PMID:25582706

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily a, polypeptide 1

decreases activity

Cholic Acid results in decreased activity of CYP2A1 protein

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily a, polypeptide 3

increases expression

Cholic Acid results in increased expression of CYP2A4 mRNA

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

Cholic Acid results in increased expression of CYP2B13 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression

Cholic Acid results in increased expression of CYP2B10 mRNA

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

decreases activity

Cholic Acid results in decreased activity of CYP2C11 protein

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases activity
multiple interactions

Cholic Acid results in decreased activity of CYP3A2 protein
[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid
Cholic Acid metabolite results in decreased activity of CYP3A4 protein
Cholic Acid promotes the reaction [CYP3A4 protein results in increased oxidation of 7-benzyloxy-4-trifluoromethylcoumarin]

PMID:8889968 PMID:19299527 PMID:27871908 PMID:34461081

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions

[CYP3A23-3A1 gene mutant form co-treated with CYP3A2 gene mutant form] results in increased abundance of Cholic Acid

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
decreases expression

[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased activity of CYP7A1 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of CYP7A1 mRNA
Cholic Acid results in decreased expression of CYP7A1 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA

PMID:12072388 PMID:14684380 PMID:15694933 PMID:17521389 PMID:20671298 More...

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

decreases expression

Cholic Acid results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

decreases expression

Cholic Acid results in decreased expression of CYP8B1 mRNA

PMID:17521389 PMID:25055961 PMID:25582706

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions

[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein; Acetylcysteine inhibits the reaction [[bisphenol A co-treated with Dietary Fats co-treated with Cholesterol co-treated with Cholic Acid] results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

fatty acid binding protein 6

increases expression

Cholic Acid results in increased expression of FABP6 mRNA

PMID:25582706 PMID:35584729

NCBI chr10:28,063,603...28,068,276
Ensembl chr10:28,063,603...28,068,282

G

fatty acid synthase

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

multiple interactions
increases expression

[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter
Cholic Acid results in increased expression of FGF15 mRNA
Cholic Acid results in increased expression of FGF19 mRNA

PMID:22561792 PMID:25055961 PMID:25582706

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

flavin containing dimethylaniline monoxygenase 3

increases expression

Cholic Acid results in increased expression of FMO3 mRNA

NCBI chr13:75,309,367...75,334,915
Ensembl chr13:75,309,374...75,328,028

G

flavin containing dimethylaniline monoxygenase 4

increases expression

Cholic Acid results in increased expression of FMO4 mRNA

NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874

G

FOS like 1, AP-1 transcription factor subunit

increases expression

Cholic Acid results in increased expression of FOSL1 protein

NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930

G

G protein-coupled bile acid receptor 1

multiple interactions
increases expression

Cholic Acid binds to and results in increased activity of GPBAR1 protein
Cholic Acid results in increased expression of GPBAR1 mRNA

PMID:18180267 PMID:25055961

NCBI chr 9:75,860,758...75,863,260
Ensembl chr 9:75,860,677...75,863,168

G

glutathione S-transferase alpha 1

multiple interactions

Cholic Acid binds to [GSTA1 protein co-treated with GSTA1 protein]; Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]]

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase alpha 2

increases expression

Cholic Acid results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase alpha 3

multiple interactions

Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]; Glutathione inhibits the reaction [Cholic Acid binds to [GSTA3 protein co-treated with GSTA1 protein]]

NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240

G

glutathione S-transferase alpha 4

multiple interactions

Cholic Acid binds to and results in decreased activity of GSTA4 protein

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase mu 1

multiple interactions

Cholic Acid binds to and results in decreased activity of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

multiple interactions
increases expression

Cholic Acid binds to and results in decreased activity of GSTM2 protein
Cholic Acid results in increased expression of GSTM2 mRNA

PMID:3954743 PMID:17521389

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase, mu 5

increases expression

Cholic Acid results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

helicase, lymphoid specific

increases expression

Cholic Acid results in increased expression of HELLS protein

NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844

G

3-hydroxy-3-methylglutaryl-CoA reductase

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA; [Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HMGCR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of HMGCR protein]

NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703

G

hepatocyte nuclear factor 4, alpha

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of HNF4A mRNA]

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

hydroxysteroid 11-beta dehydrogenase 1

increases abundance

HSD11B1 gene mutant form results in increased abundance of Cholic Acid

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

interleukin 1 beta

multiple interactions

[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of IL1B mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]

PMID:12072388 PMID:27151938

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor-like 1

increases expression

Cholic Acid results in increased expression of IL1RL1 protein

NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256

G

lecithin cholesterol acyltransferase

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LCAT protein]

NCBI chr19:33,834,748...33,838,214
Ensembl chr19:33,834,403...33,838,231

G

low density lipoprotein receptor

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased expression of LDLR mRNA]

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

lipoprotein lipase

multiple interactions

[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of LPL mRNA; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in increased activity of LPL protein]

PMID:14684380 PMID:30273964

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

LDL receptor related protein 2

increases expression
multiple interactions

Cholic Acid results in increased expression of LRP2 protein
NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]

NCBI chr 3:54,189,305...54,346,769
Ensembl chr 3:54,189,308...54,346,708

G

microtubule-associated protein 1 light chain 3 beta

increases expression

Cholic Acid results in increased expression of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions
increases activity

[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK1 protein
Cholic Acid results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases activity

[Diethylnitrosamine co-treated with Cholic Acid] results in increased activity of and results in increased phosphorylation of MAPK3 protein
Cholic Acid results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

minichromosome maintenance complex component 3

increases expression

Cholic Acid results in increased expression of MCM3 protein

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

microsomal glutathione S-transferase 3

increases expression

Cholic Acid results in increased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

metallothionein 1

increases expression

Cholic Acid results in increased expression of MT1 mRNA

NCBI chr19:10,826,032...10,827,048
Ensembl chr19:10,826,032...10,827,049
Ensembl chr17:10,826,032...10,827,049
Ensembl chr X:10,826,032...10,827,049

G

mucin 2, oligomeric mucus/gel-forming

decreases expression

Cholic Acid results in decreased expression of MUC2 mRNA

NCBI chr 1:196,799,494...196,831,740
Ensembl chr 1:196,799,517...196,831,756

G

myosin light chain 9

increases phosphorylation

Cholic Acid results in increased phosphorylation of MYL9 protein

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

NFE2 like bZIP transcription factor 2

increases expression

Cholic Acid results in increased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

increases phosphorylation
multiple interactions

Cholic Acid results in increased phosphorylation of NFKBIA protein
Cholic Acid promotes the reaction [Diethylnitrosamine results in increased phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

NAD(P)H quinone dehydrogenase 1

increases expression

Cholic Acid results in increased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
increases expression

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR0B2 mRNA
Cholic Acid results in increased expression of NR0B2 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; IL1B protein inhibits the reaction [Cholic Acid results in increased expression of NR0B2 mRNA]

PMID:12072388 PMID:14684380 PMID:15694933 PMID:16002565 PMID:16269825 More...

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 3

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H3 protein; [Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of NR1H3 mRNA]

PMID:14684380 PMID:33845646

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group H, member 4

affects binding
decreases expression
increases phosphorylation
increases expression
multiple interactions
increases activity

Cholic Acid binds to NR1H4 protein
Cholic Acid results in decreased expression of NR1H4 mRNA
Cholic Acid results in increased phosphorylation of NR1H4 protein
Cholic Acid results in increased expression of NR1H4 mRNA
[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of CYP7A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of ABCB11 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of NR0B2 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCA9 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCB11 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG5 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ABCG8 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of ATP8B1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA; Cholic Acid binds to and results in increased activity of NR1H4 protein; Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]; Cholic Acid results in increased phosphorylation of and results in increased activity of NR1H4 protein; NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]; NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]; NR1H4 protein promotes the reaction [Cholic Acid results in increased expression of LRP2 protein]
[[Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter] which results in increased expression of FGF19 mRNA; [Cholic Acid results in increased activity of NR1H4 protein] which binds to FGF19 promoter; Cholic Acid analog binds to and results in increased activity of NR1H4 protein; Cholic Acid binds to and results in increased activity of NR1H4 protein
[Cholesterol, Dietary co-treated with Cholic Acid] results in increased activity of NR1H4 protein

PMID:13130122 PMID:14684380 PMID:15375181 PMID:15694933 PMID:19965603 More...

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 2

increases expression
increases activity

Cholic Acid results in increased expression of NR1I2 mRNA
Cholic Acid metabolite results in increased activity of NR1I2 protein; Cholic Acid results in increased activity of NR1I2 protein

PMID:25582706 PMID:27871908

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

orosomucoid 1

increases expression

Cholic Acid results in increased expression of ORM1 protein

NCBI chr 5:76,766,637...76,776,149
Ensembl chr 5:76,772,941...76,776,154

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

increases expression

Cholic Acid results in increased expression of PAPSS2 mRNA

NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331

G

proliferating cell nuclear antigen

increases expression
multiple interactions

Cholic Acid results in increased expression of PCNA protein
[Diethylnitrosamine co-treated with Cholic Acid] results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phosphoinositide-3-kinase, regulatory subunit 5

increases expression

Cholic Acid results in increased expression of PIK3R5 protein

NCBI chr10:53,132,585...53,200,663
Ensembl chr10:53,132,603...53,199,374

G

paraoxonase 1

decreases expression
multiple interactions

Cholic Acid results in decreased expression of PON1 mRNA; Cholic Acid results in decreased expression of PON1 protein
[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein; Atorvastatin inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]; Proanthocyanidins inhibits the reaction [[Cholesterol co-treated with Cholic Acid] results in decreased secretion of PON1 protein]

PMID:16269825 PMID:30273964

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

cytochrome p450 oxidoreductase

increases expression
decreases abundance

Cholic Acid results in increased expression of POR mRNA
POR gene mutant form results in decreased abundance of Cholic Acid

PMID:17521389 PMID:25034404

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator activated receptor alpha

decreases abundance
multiple interactions

PPARA gene mutant form results in decreased abundance of Cholic Acid
[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in decreased expression of PPARA mRNA]

PMID:29175453 PMID:33845646

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

RAB7A, member RAS oncogene family

decreases expression

Cholic Acid results in decreased expression of RAB7 protein

NCBI chr 4:120,461,966...120,510,756
Ensembl chr 4:120,461,963...120,506,889

G

regenerating family member 3 beta

decreases expression

Cholic Acid results in decreased expression of REG3B mRNA

NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015

G

regenerating family member 3 gamma

decreases expression

Cholic Acid results in decreased expression of REG3G mRNA

NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Cholic Acid promotes the reaction [Diethylnitrosamine results in increased expression of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

replication timing regulatory factor 1

increases expression

Cholic Acid results in increased expression of RIF1 protein

NCBI chr 3:36,554,689...36,607,961
Ensembl chr 3:36,554,697...36,603,617

G

scavenger receptor class B, member 1

multiple interactions

[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SCARB1 mRNA; [NR1H4 protein mutant form inhibits the reaction [Cholic Acid results in increased phosphorylation of NR1H4 protein]] which results in decreased expression of SCARB1 mRNA

PMID:22540009 PMID:30996006

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

solute carrier family 10 member 1

multiple interactions
decreases expression

[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in decreased expression of SLC10A1 mRNA
Cholic Acid results in decreased expression of SLC10A1 mRNA; Cholic Acid results in decreased expression of SLC10A1 protein

PMID:11438506 PMID:16002565 PMID:17521389 PMID:22540009 PMID:25055961 More...

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 10 member 2

decreases expression
affects expression

Cholic Acid results in decreased expression of SLC10A2 mRNA
Cholic Acid affects the expression of SLC10A2 mRNA
Cholic Acid results in decreased expression of SLC10A2 protein

PMID:25582706 PMID:35584729

NCBI chr16:84,386,528...84,409,475
Ensembl chr16:84,374,862...84,409,475

G

solute carrier family 22 member 20

increases expression

Cholic Acid results in increased expression of SLC22A20 mRNA

NCBI chr 1:203,257,374...203,273,854
Ensembl chr 1:203,257,374...203,273,822

G

solute carrier family 27 member 5

multiple interactions

Cholic Acid inhibits the reaction [SLC27A5 protein results in increased uptake of Fatty Acids]

NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172

G

solute carrier family 2 member 1

increases expression

Cholic Acid results in increased expression of SLC2A1 protein

NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416

G

solute carrier family 51 member A

increases expression

Cholic Acid results in increased expression of SLC51A mRNA

PMID:25055961 PMID:25582706

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

multiple interactions
increases expression

[Cholic Acid binds to and results in increased activity of NR1H4 protein] which results in increased expression of SLC51B mRNA
Cholic Acid results in increased expression of SLC51B mRNA

PMID:22540009 PMID:22961653 PMID:25055961 PMID:25582706

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier organic anion transporter family, member 1a4

increases expression

Cholic Acid results in increased expression of SLCO1A4 mRNA

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

increases uptake
increases expression

SLCO1B2 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B3 mRNA
SLCO1B3 protein results in increased uptake of Cholic Acid
Cholic Acid results in increased expression of SLCO1B2 mRNA

PMID:16534140 PMID:20949553 PMID:25055961 PMID:25582706

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 2b1

multiple interactions
increases uptake

Rutin promotes the reaction [SLCO2B1 protein results in increased uptake of Cholic Acid]

NCBI chr 1:153,959,288...154,007,294
Ensembl chr 1:153,959,293...154,007,353

G

superoxide dismutase 3

multiple interactions
increases expression

NR1H4 gene mutant form inhibits the reaction [Cholic Acid results in increased expression of SOD3 mRNA]

NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990

G

sequestosome 1

increases expression

Cholic Acid results in increased expression of SQSTM1 protein

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

SRC proto-oncogene, non-receptor tyrosine kinase

multiple interactions

Cholic Acid promotes the reaction [SRC protein binds to NR1H4 protein]

NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476

G

sterol regulatory element binding transcription factor 1

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of SREBF1 mRNA]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

stathmin 1

increases expression

Cholic Acid results in increased expression of STMN1 protein

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

sulfotransferase family 2A member 1

increases sulfation
increases expression

SULT2A1 protein results in increased sulfation of Cholic Acid
Cholic Acid results in increased expression of SULT2A1 mRNA

PMID:17521389 PMID:20102295 PMID:22961653

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

transferrin receptor

increases expression

Cholic Acid results in increased expression of TFRC protein

NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257

G

tumor necrosis factor

increases expression
multiple interactions

Cholic Acid results in increased expression of TNF mRNA
Diethylnitrosamine promotes the reaction [Cholic Acid results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

troponin I3, cardiac type

multiple interactions

[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein; zingerone inhibits the reaction [[Cholesterol, Dietary co-treated with Cholic Acid] results in increased expression of TNNI3 protein]

NCBI chr 1:69,299,900...69,303,582
Ensembl chr 1:69,299,900...69,303,580

G

vitamin D receptor

increases localization

Cholic Acid results in increased localization of VDR protein

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

G

vascular endothelial growth factor A

increases expression

Cholic Acid results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

digoxigenin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases transport

ABCB1 protein results in increased transport of Digoxigenin

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

C-C motif chemokine ligand 2

decreases expression

Digoxigenin results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 4

decreases expression

Digoxigenin results in decreased expression of CCL4 protein

NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
increases expression

Digoxigenin promotes the reaction [RORC protein binds to G6PC1 promoter]
Digoxigenin results in increased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

interleukin 17A

multiple interactions

Digoxigenin results in increased expression of and results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 17F

multiple interactions

Digoxigenin results in increased expression of and results in increased secretion of IL17F protein

NCBI chr 9:23,190,094...23,201,482
Ensembl chr 9:23,190,100...23,201,482

G

interleukin 6 receptor

decreases expression

Digoxigenin results in decreased expression of IL6R protein modified form

NCBI chr 2:175,289,157...175,347,719
Ensembl chr 2:175,298,686...175,347,536

G

neuronal PAS domain protein 2

increases expression
multiple interactions

Digoxigenin results in increased expression of NPAS2 mRNA
Digoxigenin promotes the reaction [RORC protein binds to NPAS2 promoter]

NCBI chr 9:41,463,361...41,642,322
Ensembl chr 9:41,463,830...41,642,320

G

RAR-related orphan receptor C

increases expression
multiple interactions

Digoxigenin results in increased expression of RORC mRNA
Digoxigenin promotes the reaction [RORC protein binds to G6PC1 promoter]; Digoxigenin promotes the reaction [RORC protein binds to NPAS2 promoter]; RORC protein promotes the reaction [Digoxigenin results in increased expression of RORC mRNA]

NCBI chr 2:182,009,707...182,034,910
Ensembl chr 2:182,009,286...182,034,907

G

vascular endothelial growth factor A

decreases expression

Digoxigenin results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

ginsenoside C-K

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

C-X-C motif chemokine receptor 1

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]

NCBI chr 9:75,766,894...75,771,079
Ensembl chr 9:75,766,770...75,771,084

G

intercellular adhesion molecule 1

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interferon gamma

decreases expression

ginsenoside M1 results in decreased expression of IFNG mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

decreases expression

ginsenoside M1 results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 4

decreases expression

ginsenoside M1 results in decreased expression of IL4 mRNA

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

ginsenoside M1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha 4

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]

NCBI chr 3:64,162,764...64,235,010
Ensembl chr 3:64,163,085...64,233,715

G

integrin subunit alpha L

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit beta 1

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

integrin subunit beta 2

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

matrix metallopeptidase 9

decreases secretion

ginsenoside M1 results in decreased secretion of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

nuclear factor kappa B subunit 1

multiple interactions

ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

ginsenoside M1 results in decreased expression of and results in decreased activity of NOS2 protein

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

purinergic receptor P2X 4

multiple interactions

[ginsenoside M1 co-treated with Adenosine Triphosphate] results in increased activity of P2RX4 protein; ginsenoside M1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

purinergic receptor P2X 7

decreases response to substance

P2RX7 gene mutant form results in decreased susceptibility to ginsenoside M1

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

prostaglandin-endoperoxide synthase 2

decreases expression

ginsenoside M1 results in decreased expression of PTGS2 mRNA
ginsenoside M1 results in decreased expression of PTGS2 protein

PMID:15802804 PMID:15914323

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside M1 results in decreased activity of [NFKB1 protein binds to RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

selectin E

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

tumor necrosis factor

multiple interactions
decreases expression
decreases response to substance

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGA4 protein binds to ITGB1 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of [ITGAL protein binds to ITGB2 protein]]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of CXCR1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of ICAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of SELE protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]; ginsenoside M1 inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]
ginsenoside M1 results in decreased expression of TNF mRNA
ginsenoside M1 results in decreased susceptibility to TNF protein

PMID:15914323 PMID:21875580

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular cell adhesion molecule 1

multiple interactions

ginsenoside M1 inhibits the reaction [TNF protein results in increased expression of VCAM1 protein]

NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958

ginsenoside F1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

interleukin 6

multiple interactions

ginsenoside F1 inhibits the reaction [Galactose results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside F1 inhibits the reaction [Galactose affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

ginsenoside F2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

ginsenoside F2 analog inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

ginsenoside Rb1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

ATPase H+ transporting V1 subunit A

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1A mRNA]

NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694

G

ATPase H+ transporting V1 subunit B2

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of ATP6V1B2 mRNA]

NCBI chr16:20,617,515...20,641,651
Ensembl chr16:20,617,518...20,641,745

G

bone morphogenetic protein 2

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of BMP2 mRNA]
ginsenoside Rb1 results in increased expression of BMP2 mRNA

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

caspase 1

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

chloride voltage-gated channel 7

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CLCN7 mRNA]

NCBI chr10:14,151,758...14,177,130
Ensembl chr10:14,151,758...14,177,130

G

cathepsin B

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSB mRNA]

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of CTSD mRNA]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

gasdermin D

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased cleavage of GSDMD protein]

NCBI chr 7:107,542,489...107,547,051
Ensembl chr 7:107,542,083...107,547,055

G

heme oxygenase 1

multiple interactions
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Cycloheximide inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Dactinomycin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]; ginsenoside Rb1 results in increased expression of and results in increased activity of HMOX1 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 mRNA]; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased expression of HMOX1 protein]
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein

PMID:19781563 PMID:25422538

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

insulin-like growth factor 1

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of IGF1 mRNA]
ginsenoside Rb1 results in increased expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 18

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL18 protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL18 protein]

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of and results in increased secretion of IL1B protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

integrin subunit alpha M

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGAM protein]

NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503

G

integrin subunit beta 2

multiple interactions

ginsenoside Rb1 inhibits the reaction [Lipopolysaccharides results in increased expression of ITGB2 protein]

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

potassium voltage-gated channel subfamily E regulatory subunit 1

increases expression

ginsenoside Rb1 results in increased expression of KCNE1

NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901

G

potassium voltage-gated channel subfamily H member 2

affects activity

ginsenoside Rb1 affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysosomal-associated membrane protein 1

multiple interactions

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of LAMP1 mRNA]

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

lactate dehydrogenase A

multiple interactions

Chloroquine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased secretion of LDHA protein]

NCBI chr 1:97,371,823...97,381,247
Ensembl chr 1:97,366,021...97,433,472

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]]; ginsenoside Rb1 promotes the reaction [alpha-Chlorohydrin results in increased lipidation of and results in increased localization of MAP1LC3B protein]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

microtubule-associated protein 2

increases expression

ginsenoside Rb1 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

nuclear factor of activated T-cells 1

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]

NCBI chr18:74,046,422...74,156,041
Ensembl chr18:74,046,904...74,156,028

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization
increases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; [ginsenoside Rb1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein; fulvestrant inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]; ginsenoside Rb1 results in increased activity of and results in increased localization of NFE2L2 protein; Pertussis Toxin inhibits the reaction [ginsenoside Rb1 results in increased localization of NFE2L2 protein]
ginsenoside Rb1 affects the localization of NFE2L2 protein
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein
ginsenoside Rb1 results in increased expression of NFE2L2 mRNA

PMID:19781563 PMID:22780686 PMID:25422538

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NLR family, pyrin domain containing 3

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of NLRP3 protein]

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

purinergic receptor P2X 4

multiple interactions

ginsenoside Rb1 promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

progesterone receptor

increases expression

ginsenoside Rb1 results in increased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

PTEN induced kinase 1

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]

NCBI chr 5:150,530,523...150,542,635
Ensembl chr 5:150,530,523...150,542,635

G

parkin RBR E3 ubiquitin protein ligase

multiple interactions

Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]

NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

RUNX family transcription factor 2

increases expression
multiple interactions

ginsenoside Rb1 results in increased expression of RUNX2 mRNA
ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of RUNX2 mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ginsenoside Rb1 binds to and results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

sequestosome 1

multiple interactions
decreases expression

ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]
Cyclosporine inhibits the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]
ginsenoside Rb1 results in decreased expression of SQSTM1 protein

PMID:34812491 PMID:38373586

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

transcription factor EB

multiple interactions

[ginsenoside Rb1 co-treated with alpha-Chlorohydrin] affects the localization of TFEB protein; ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of TFEB mRNA]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]
ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of and affects the localization of TFEB protein]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PARK protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in decreased expression of PINK1 protein]]; TFEB protein promotes the reaction [ginsenoside Rb1 inhibits the reaction [alpha-Chlorohydrin results in increased expression of SQSTM1 protein]]

PMID:34812491 PMID:38373586

NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714

G

transforming growth factor, beta 1

multiple interactions
increases expression

ginsenoside Rb1 inhibits the reaction [aluminum chloride results in decreased expression of TGFB1 mRNA]
ginsenoside Rb1 results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

multiple interactions

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF superfamily member 11

multiple interactions
decreases response to substance

ginsenoside Rb1 inhibits the reaction [TNFSF11 protein affects the localization of RELA protein]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of FOS mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of NFATC1 mRNA]; ginsenoside Rb1 inhibits the reaction [TNFSF11 protein results in increased expression of TNF mRNA]
ginsenoside Rb1 results in decreased susceptibility to TNFSF11 protein

NCBI chr15:53,673,850...53,705,325
Ensembl chr15:53,673,877...53,705,445

ginsenoside Rb2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

increases expression

ginsenoside Rb2 results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

lipoprotein lipase

increases secretion
decreases secretion

ginsenoside Rb2 results in increased secretion of LPL protein
ginsenoside Rb2 results in decreased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

ginsenoside Rc

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ginsenoside Rc binds to and results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

ginsenoside Rd

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

AKT serine/threonine kinase 1

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]; ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of BAX mRNA]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in decreased expression of BCL2 mRNA]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CASP3 protein modified form]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

increases expression

ginsenoside Rd results in increased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1A

increases expression
multiple interactions

ginsenoside Rd results in increased expression of CDKN1A mRNA
staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CDKN1A mRNA]

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

choline O-acetyltransferase

increases expression
multiple interactions

ginsenoside Rd results in increased expression of CHAT mRNA; ginsenoside Rd results in increased expression of CHAT protein
staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Rd results in increased expression of CHAT protein]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

cytochrome c, somatic

multiple interactions

ginsenoside Rd inhibits the reaction [APP protein modified form results in increased expression of CYCS mRNA]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

lipoprotein lipase

decreases secretion

ginsenoside Rd results in decreased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

microtubule-associated protein 2

increases expression

ginsenoside Rd results in increased expression of MAP2 mRNA; ginsenoside Rd results in increased expression of MAP2 protein

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

ginsenoside Rd results in increased phosphorylation of and results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nerve growth factor

increases expression

ginsenoside Rd results in increased expression of NGF mRNA

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

increases expression

ginsenoside Rd results in increased expression of NGFR mRNA; ginsenoside Rd results in increased expression of NGFR protein

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

purinergic receptor P2X 4

multiple interactions

ginsenoside Rd promotes the reaction [Adenosine Triphosphate results in increased activity of P2RX4 protein]

NCBI chr12:33,844,609...33,862,265
Ensembl chr12:33,844,396...33,862,253

G

purinergic receptor P2X 7

decreases response to substance

P2RX7 gene mutant form results in decreased susceptibility to ginsenoside Rd

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

solute carrier family 18 member A3

increases expression

ginsenoside Rd results in increased expression of SLC18A3 mRNA

NCBI chr16:7,713,630...7,716,491

G

solute carrier family 5 member 7

increases expression

ginsenoside Rd results in increased expression of SLC5A7 mRNA

NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258

G

solute carrier organic anion transporter family member 1B2

multiple interactions

ginsenoside Rd binds to and results in decreased activity of SLCO1B3 protein

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

ginsenoside Re

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases transport

ABCB11 protein results in increased transport of ginsenoside Re

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 1

increases transport

ABCC1 protein results in increased transport of ginsenoside Re

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases transport

ABCC2 protein results in increased transport of ginsenoside Re

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily G member 2

increases transport

ABCG2 protein results in increased transport of ginsenoside Re

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

adiponectin, C1Q and collagen domain containing

increases expression
multiple interactions

ginsenoside Re results in increased expression of ADIPOQ mRNA
ginsenoside Re results in increased expression of and results in increased secretion of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

allograft inflammatory factor 1

multiple interactions
decreases expression

3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of AIF1 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]
ginsenoside Re results in decreased expression of AIF1 protein

PMID:29467000 PMID:36682417

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

ginsenoside Re results in increased phosphorylation of and results in increased activity of AKT1 protein
ginsenoside Re results in increased phosphorylation of AKT1 protein

PMID:17878692 PMID:17885204 PMID:24599032

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

androgen receptor

multiple interactions

ginsenoside Re binds to and affects the activity of AR protein

NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925

G

BCL2 associated X, apoptosis regulator

decreases expression
multiple interactions

ginsenoside Re results in decreased expression of BAX mRNA; ginsenoside Re results in decreased expression of BAX protein
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; Acetylcysteine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; Cyclosporine inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of BAX protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]

PMID:12674765 PMID:15621629 PMID:29467000 PMID:37308051

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
multiple interactions

ginsenoside Re results in increased expression of BCL2 mRNA; ginsenoside Re results in increased expression of BCL2 protein
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of BCL2 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]

PMID:15621629 PMID:29467000 PMID:37308051

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions

3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased expression of BCL2L1 protein]

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 3

multiple interactions

3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased activity of CASP3 protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of CASP3 protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re results in decreased cleavage of and results in decreased activity of CASP3 protein; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]

PMID:15621629 PMID:23102375 PMID:25523949 PMID:29467000 PMID:37308051

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase inhibitor 1A

increases expression

ginsenoside Re results in increased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

choline O-acetyltransferase

increases expression
multiple interactions

ginsenoside Re results in increased expression of CHAT mRNA; ginsenoside Re results in increased expression of CHAT protein
staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT mRNA]; staurosporine aglycone inhibits the reaction [ginsenoside Re results in increased expression of CHAT protein]

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

claudin 1

multiple interactions

ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of CLDN1 protein]

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

C-reactive protein

increases expression

ginsenoside Re results in increased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

cytochrome b-245 alpha chain

multiple interactions

ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [Phencyclidine results in increased activity of CYBA protein]

NCBI chr19:50,487,598...50,495,669
Ensembl chr19:50,487,597...50,495,721

G

cytochrome P450 family 8 subfamily B member 1

increases expression

ginsenoside Re results in increased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

estrogen receptor 1

multiple interactions

ginsenoside Re binds to and affects the activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

fatty acid binding protein 4

increases expression

ginsenoside Re results in increased expression of FABP4 mRNA

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

decreases expression
multiple interactions

ginsenoside Re results in decreased expression of FAS mRNA
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of FAS mRNA]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ginsenoside Re results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glucose-6-phosphatase catalytic subunit 1

decreases expression

ginsenoside Re results in decreased expression of G6PC1 mRNA

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

glycerol-3-phosphate acyltransferase, mitochondrial

multiple interactions

ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of GPAM mRNA]

NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639

G

glutathione peroxidase 1

multiple interactions

ginsenoside Re affects the reaction [GPX1 protein affects the expression of AIF1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of CYBA protein]]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]

PMID:29037473 PMID:36682417

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glycogen synthase kinase 3 beta

increases phosphorylation

ginsenoside Re results in increased phosphorylation of GSK3B protein

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

heat shock protein family D (Hsp60) member 1

increases expression

ginsenoside Re results in increased expression of HSPD1 protein

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

interferon gamma

decreases expression

ginsenoside Re results in decreased expression of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 1 beta

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of IL1B mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL1B mRNA]

PMID:16557482 PMID:22494059 PMID:22849695

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]]

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

interleukin-1 receptor-associated kinase 1

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK1 protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of IRAK1 protein]

NCBI chr X:151,768,621...151,778,521
Ensembl chr X:151,768,777...151,778,521

G

interleukin-1 receptor-associated kinase 4

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased degradation of IRAK4 protein]

NCBI chr 7:125,682,502...125,708,294
Ensembl chr 7:125,682,488...125,717,837

G

immunity-related GTPase M

decreases expression

ginsenoside Re results in decreased expression of IRGM protein

NCBI chr10:33,233,513...33,241,594
Ensembl chr10:33,233,455...33,241,578

G

insulin receptor substrate 1

multiple interactions
increases expression
increases phosphorylation

ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]
ginsenoside Re results in increased expression of IRS1 mRNA
ginsenoside Re results in increased phosphorylation of IRS1 protein

PMID:17885204 PMID:23545455

NCBI chr 9:83,552,964...83,605,797
Ensembl chr 9:83,548,944...83,606,122

G

potassium voltage-gated channel subfamily E regulatory subunit 1

increases expression

ginsenoside Re results in increased expression of KCNE1

NCBI chr11:31,580,951...31,594,116
Ensembl chr11:31,580,742...31,593,901

G

lipoprotein lipase

increases secretion

ginsenoside Re results in increased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

leucine-rich pentatricopeptide repeat containing

increases expression

ginsenoside Re results in increased expression of LRPPRC protein

NCBI chr 6:9,859,816...9,942,294
Ensembl chr 6:9,859,867...9,942,293

G

microtubule-associated protein 2

increases expression

ginsenoside Re results in increased expression of MAP2 mRNA; ginsenoside Re results in increased expression of MAP2 protein

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK1 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK1 protein
ginsenoside Re results in increased phosphorylation of MAPK1 protein

PMID:24599032 PMID:36682417

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

ginsenoside Re affects the reaction [GPX1 protein affects the phosphorylation of MAPK3 protein]; ginsenoside Re results in increased phosphorylation of and results in increased activity of MAPK3 protein
ginsenoside Re results in increased phosphorylation of MAPK3 protein

PMID:24599032 PMID:36682417

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myeloperoxidase

multiple interactions

ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

myosin light chain 9

affects phosphorylation

ginsenoside Re affects the phosphorylation of MYL9 protein

NCBI chr 3:145,281,943...145,288,333
Ensembl chr 3:145,281,937...145,288,333

G

myosin light chain kinase

affects expression

ginsenoside Re affects the expression of MYLK mRNA; ginsenoside Re affects the expression of MYLK protein

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261

G

neutrophil cytosolic factor 1

multiple interactions

ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine affects the localization of NCF1 protein]]; ginsenoside Re inhibits the reaction [Phencyclidine affects the localization of NCF1 protein]

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

NFKB inhibitor alpha

multiple interactions

ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

increases expression

ginsenoside Re results in increased expression of NGF mRNA

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

nerve growth factor receptor

increases expression

ginsenoside Re results in increased expression of NGFR mRNA; ginsenoside Re results in increased expression of NGFR protein

NCBI chr10:80,515,287...80,533,518
Ensembl chr10:80,515,299...80,533,518

G

nitric oxide synthase 2

multiple interactions
decreases expression

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]
ginsenoside Re results in decreased expression of NOS2 protein

PMID:15621629 PMID:23102375

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

multiple interactions
increases phosphorylation

2-aminoethoxydiphenyl borate inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Calcium deficiency inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]; Mifepristone inhibits the reaction [ginsenoside Re results in increased phosphorylation of NOS3 protein]

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

nuclear receptor subfamily 0, group B, member 2

increases expression

ginsenoside Re results in increased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions
increases activity

[ginsenoside Re results in increased activity of NR3C1 protein] which results in increased abundance of Nitric Oxide

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

occludin

multiple interactions

ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of OCLN protein]

NCBI chr 2:31,657,217...31,707,466
Ensembl chr 2:31,657,220...31,764,150

G

poly (ADP-ribose) polymerase 1

multiple interactions

ginsenoside Re inhibits the reaction [Methamphetamine results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
decreases expression

ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of PCK1 mRNA]
ginsenoside Re results in decreased expression of PCK1 mRNA

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

prodynorphin

multiple interactions

3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]]; 3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of PDYN mRNA]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of BCL2 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased cleavage of CASP3 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of AIF1 protein]]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in increased expression of BAX protein]]]

NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334

G

progesterone receptor

multiple interactions
increases expression

ginsenoside Re binds to and affects the activity of PGR protein
ginsenoside Re results in increased expression of PGR protein

PMID:16204943 PMID:16985185

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

peroxisome proliferator-activated receptor gamma

increases expression

ginsenoside Re results in increased expression of PPARG mRNA

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

protein kinase AMP-activated catalytic subunit alpha 1

increases phosphorylation
multiple interactions

ginsenoside Re results in increased phosphorylation of PRKAA1 protein
ginsenoside Re inhibits the reaction [Dietary Fats results in decreased phosphorylation of PRKAA1 protein]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase C, delta

multiple interactions
increases response to substance

3-nitropropionic acid inhibits the reaction [ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]]; ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in increased cleavage of and results in increased phosphorylation of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of CAT protein]]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]]
ginsenoside Re inhibits the reaction [Methamphetamine affects the localization of PRKCD protein]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of and results in increased cleavage of PRKCD protein]
PRKCD results in increased susceptibility to ginsenoside Re

PMID:24430743 PMID:25523949 PMID:37308051

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

platelet-activating factor receptor

multiple interactions
decreases expression

ginsenoside Re affects the reaction [GPX1 protein affects the expression of PTAFR protein]
ginsenoside Re results in decreased expression of PTAFR protein

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 2

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of PTGS2 mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of PTGS2 mRNA]

PMID:16557482 PMID:23102375

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

ginsenoside Re affects the reaction [GPX1 protein affects the expression of and affects the localization of RELA protein]; ginsenoside Re results in decreased expression of and affects the localization of RELA protein

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

ribosomal protein S6 kinase B1

increases phosphorylation

ginsenoside Re results in increased phosphorylation of RPS6KB1 protein

NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908

G

stearoyl-CoA desaturase

decreases expression
multiple interactions

ginsenoside Re results in decreased expression of SCD mRNA
ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SCD1 mRNA]

NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562

G

solute carrier family 18 member A3

increases expression

ginsenoside Re results in increased expression of SLC18A3 mRNA

NCBI chr16:7,713,630...7,716,491

G

solute carrier family 2 member 4

multiple interactions
increases localization

ginsenoside Re inhibits the reaction [Dietary Fats inhibits the reaction [INS1 protein results in increased localization of SLC2A4 protein]]
ginsenoside Re results in increased localization of SLC2A4 protein

PMID:17885204 PMID:22571876 PMID:23545455

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 5 member 7

increases expression

ginsenoside Re results in increased expression of SLC5A7 mRNA

NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258

G

solute carrier organic anion transporter family member 1B2

multiple interactions

SLCO1B2 protein binds to and results in increased transport of ginsenoside Re
SLCO1B3 protein binds to and results in increased transport of ginsenoside Re

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

suppressor of cytokine signaling 3

multiple interactions

ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 1

multiple interactions
decreases activity

ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in increased activity of SOD1 protein]]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]; PRKCD affects the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased activity of SOD1 protein]]
ginsenoside Re results in decreased activity of SOD1 protein

PMID:24430743 PMID:29037473 PMID:36682417

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

ginsenoside Re inhibits the reaction [3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester results in decreased activity of SOD2 protein]; ginsenoside Re inhibits the reaction [GPX1 protein affects the reaction [Phencyclidine results in decreased activity of SOD2 protein]]

PMID:29037473 PMID:37308051

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

ginsenoside Re inhibits the reaction [Dietary Fats results in increased expression of SREBF1 mRNA]
ginsenoside Re results in decreased expression of SREBF1 mRNA

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

serine/threonine kinase 11

increases phosphorylation

ginsenoside Re results in increased phosphorylation of STK11 protein

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

G

tachykinin, precursor 1

multiple interactions

ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]; ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 mRNA]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [Methamphetamine results in increased expression of TAC1 protein modified form]]

NCBI chr 4:35,679,183...35,687,180
Ensembl chr 4:35,679,704...35,687,178

G

TBC1 domain family, member 4

increases phosphorylation

ginsenoside Re results in increased phosphorylation of TBC1D4 protein

NCBI chr15:78,256,030...78,434,168
Ensembl chr15:78,257,121...78,434,265

G

trefoil factor 1

increases expression

ginsenoside Re results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tyrosine hydroxylase

multiple interactions

ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of and results in decreased activity of TH protein]
3-((3,5-bis(trifluoromethyl)phenyl)methyloxy)-2-phenylpiperidine inhibits the reaction [norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]]; ginsenoside Re inhibits the reaction [Methamphetamine results in decreased expression of TH protein]; ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]; norbinaltorphimine inhibits the reaction [ginsenoside Re inhibits the reaction [PDYN gene mutant form promotes the reaction [Methamphetamine results in decreased expression of TH protein]]]

PMID:25523949 PMID:29467000

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tight junction protein 1

multiple interactions

ginsenoside Re inhibits the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of TJP1 protein]

NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432

G

toll-like receptor 4

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides binds to TLR4 protein]

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions

ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; ginsenoside Re inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased degradation of NFKBIA protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of IL6 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased expression of SOCS3 mRNA]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of CHUK protein]; ginsenoside Re inhibits the reaction [TNF protein results in increased phosphorylation of IRS1 protein]; ginsenoside Re metabolite inhibits the reaction [Oxazolone results in increased expression of TNF mRNA]; ginsenoside Re metabolite inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of TNF mRNA]; ginsenoside Re results in decreased expression of and results in decreased secretion of TNF protein

PMID:16557482 PMID:17885204 PMID:22494059 PMID:22849695 PMID:23545455

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

ginsenoside Rf

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

apolipoprotein A1

multiple interactions
decreases expression

ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]
ginsenoside Rf results in decreased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein C3

multiple interactions
decreases expression
increases expression

ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]; ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 protein]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA]
ginsenoside Rf results in decreased expression of APOC3 protein

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

potassium voltage-gated channel subfamily H member 2

affects activity

ginsenoside Rf affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

ginsenoside Rf binds to and results in decreased activity of PPARA protein; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased activity of PPARA protein]; ginsenoside Rf inhibits the reaction [pirinixic acid results in increased expression of PPARA mRNA]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOA1 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf inhibits the reaction [pirinixic acid results in decreased expression of APOC3 mRNA]]; PPARA protein affects the reaction [ginsenoside Rf results in increased expression of APOC3 mRNA]
ginsenoside Rf results in decreased expression of PPARA mRNA

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

ginsenoside Rg1

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases transport
multiple interactions

ABCB11 protein results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCB11 protein]
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCB11 protein]

PMID:25297453 PMID:29964319 PMID:32198087

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 1

increases transport

ABCC1 protein results in increased transport of ginsenoside Rg1

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

increases transport
multiple interactions
increases expression

ABCC2 protein results in increased transport of ginsenoside Rg1
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of ABCC2 protein]
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC2 protein]]
ginsenoside Rg1 results in increased expression of ABCC2 protein

PMID:25297453 PMID:29964319 PMID:32198087

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of ABCC3 protein
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]; Tretinoin inhibits the reaction [ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC3 protein]]

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of ABCC4 protein
ginsenoside Rg1 promotes the reaction [Carbon Tetrachloride results in increased expression of ABCC4 protein]

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

increases transport

ABCG2 protein results in increased transport of ginsenoside Rg1

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

acetylcholinesterase

decreases activity

ginsenoside Rg1 results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

ADAM metallopeptidase domain 10

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]

NCBI chr 8:71,346,008...71,477,889
Ensembl chr 8:71,345,837...71,477,889

G

AKT serine/threonine kinase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of AKT1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased phosphorylation of AKT1 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of AKT1 protein]
ginsenoside Rg1 inhibits the reaction [Doxorubicin results in increased expression of AKT1 mRNA]

PMID:33331133 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

apoptotic peptidase activating factor 1

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of APAF1 mRNA]

NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540

G

amyloid beta precursor protein

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in decreased expression of ADAM10 mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP mRNA]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein alternative form]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of APP protein]; ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]; ginsenoside Rg1 results in decreased susceptibility to [APP protein alternative form co-treated with Dexamethasone]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

activating transcription factor 6

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ATF6 protein]

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of ATM mRNA]

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

beta-secretase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [[APP protein alternative form co-treated with Dexamethasone] results in increased expression of BACE1 mRNA]

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

BCL2-associated agonist of cell death

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]; Mifepristone inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]; SH-6 compound inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Rotenone results in increased phosphorylation of BAD protein]]

NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823

G

BCL2 associated X, apoptosis regulator

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of BAX protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of BAX protein]
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of BAX mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein]

PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ginsenoside Rg1 results in decreased expression of BCL2 protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of BCL2 protein]

PMID:26593335 PMID:28371286 PMID:34859534 PMID:36811218

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases activity

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased activity of CASP3 protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP3 mRNA]
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP3 protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP3 protein]
ginsenoside Rg1 results in increased activity of CASP3 protein

PMID:24386346 PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases activity
multiple interactions

ginsenoside Rg1 results in increased activity of CASP9 protein
ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased cleavage of CASP9 protein]
ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CASP9 mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased cleavage of CASP9 protein]

PMID:28371286 PMID:34783124 PMID:34859534 PMID:36811218

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased activity of CAT protein]
ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of CAT protein]

PMID:29964319 PMID:37923178

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin E1

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CCNE1 protein]

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cadherin 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cyclin dependent kinase 2

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDK2 protein]

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

ginsenoside Rg1 affects the reaction [tert-Butylhydroperoxide affects the expression of CDKN1A protein]; ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of CDKN1A mRNA]

PMID:15606011 PMID:34783124

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cAMP responsive element binding protein 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP2B10 protein]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of CYP2E1 mRNA]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of CYP3A4 protein]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

DNA-damage inducible transcript 3

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of ERN1 protein]

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

ginsenoside Rg1 results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

follicle stimulating hormone subunit beta

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of FSHB protein]

NCBI chr 3:93,548,560...93,552,370
Ensembl chr 3:93,548,560...93,552,370

G

follicle stimulating hormone receptor

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of FSHR protein]

NCBI chr 6:5,198,825...5,406,785
Ensembl chr 6:5,198,825...5,406,785

G

glutamate-cysteine ligase, catalytic subunit

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of GCLC mRNA
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

increases expression
multiple interactions

ginsenoside Rg1 results in increased expression of GCLM protein
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLM protein]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

gap junction protein, alpha 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 mRNA]; ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of GJA1 protein]

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

glutamate dehydrogenase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of GLUD1 protein]

NCBI chr16:9,640,312...9,673,961
Ensembl chr16:9,640,312...9,673,957

G

glutamic--pyruvic transaminase

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glycogen synthase kinase 3 beta

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in decreased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

H2A.X variant histone

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of H2AX mRNA]

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

heme oxygenase 1

multiple interactions
increases expression

[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 mRNA; [astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] results in increased expression of HMOX1 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]
ginsenoside Rg1 results in increased expression of HMOX1 mRNA; ginsenoside Rg1 results in increased expression of HMOX1 protein

PMID:25422538 PMID:29964319

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heat shock protein family A (Hsp70) member 5

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of HSPA5 protein]

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

interferon gamma

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 1 beta

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL1B protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of IL1B protein]

PMID:22214447 PMID:29964319 PMID:32198087 PMID:36811218

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of IL6 protein]
ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of IL6 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:17655881 PMID:29964319 PMID:30918470 PMID:36811218 PMID:37923178

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit alpha

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of INHA protein]

NCBI chr 9:76,994,465...76,997,366
Ensembl chr 9:76,993,589...76,997,248

G

potassium voltage-gated channel subfamily H member 2

affects activity

ginsenoside Rg1 affects the activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

Kelch-like ECH-associated protein 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of KEAP1 protein]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

luteinizing hormone subunit beta

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of LHB protein]

NCBI chr 1:95,898,269...95,901,973
Ensembl chr 1:95,900,984...95,901,972
Ensembl chr 1:95,900,984...95,901,972

G

lipoprotein lipase

increases secretion

ginsenoside Rg1 results in increased secretion of LPL protein

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

microtubule-associated protein 2

increases expression

ginsenoside Rg1 results in increased expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

multiple interactions
affects phosphorylation

PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

affects phosphorylation
multiple interactions

ginsenoside Rg1 affects the phosphorylation of MAPK3 protein
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

mitogen-activated protein kinase 9

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of MAPK9 protein]

NCBI chr10:34,169,661...34,211,138
Ensembl chr10:34,169,675...34,210,178

G

MET proto-oncogene, receptor tyrosine kinase

multiple interactions
increases expression

Mifepristone inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

mitofusin 2

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 mRNA]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of MFN2 protein]

NCBI chr 5:158,304,285...158,335,502
Ensembl chr 5:158,304,287...158,335,342

G

microRNA 23a

decreases expression
multiple interactions

ginsenoside Rg1 results in decreased expression of MIR23A mRNA
Mifepristone inhibits the reaction [ginsenoside Rg1 results in decreased expression of MIR23A mRNA]; MIR23A mRNA inhibits the reaction [ginsenoside Rg1 results in increased expression of MET protein]

NCBI chr19:23,954,997...23,955,071
Ensembl chr19:23,954,997...23,955,071

G

matrix metallopeptidase 2

increases expression

ginsenoside Rg1 results in increased expression of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression

ginsenoside Rg1 results in increased expression of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

mechanistic target of rapamycin kinase

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]
ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of MTOR protein]

PMID:24386346 PMID:33331133

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFE2 like bZIP transcription factor 2

multiple interactions
affects localization
increases expression

[ginsenoside Rg1 co-treated with ginsenoside 20S-protopanaxatriol] results in increased expression of NFE2L2 protein
ginsenoside Rg1 affects the localization of NFE2L2 protein
[astragaloside A co-treated with ginsenoside Rg1 co-treated with ginsenoside Rb1 co-treated with notoginsenoside R1] affects the localization of NFE2L2 protein; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of GCLC mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of HMOX1 mRNA]]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NFE2L2 protein]]
ginsenoside Rg1 results in increased expression of NFE2L2 mRNA

PMID:22780686 PMID:25422538 PMID:29964319

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

NFKB inhibitor alpha

affects phosphorylation
multiple interactions

ginsenoside Rg1 affects the phosphorylation of NFKBIA protein
PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2]

PMID:22214447 PMID:29964319

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 protein]; NFE2L2 protein affects the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]; Tretinoin inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in decreased expression of NQO1 mRNA]]

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of NR1H4 protein]

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

progesterone receptor

increases expression

ginsenoside Rg1 results in increased expression of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in decreased expression of PIK3CA mRNA]

NCBI chr 2:115,175,275...115,249,034
Ensembl chr 2:115,174,984...115,249,032

G

phospholipase C, gamma 1

multiple interactions

PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK1 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of MAPK3 protein]; PLCG1 affects the reaction [ginsenoside Rg1 affects the phosphorylation of NFKBIA protein]

NCBI chr 3:149,385,587...149,416,330
Ensembl chr 3:149,385,587...149,416,330

G

protein kinase AMP-activated catalytic subunit alpha 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in increased phosphorylation of PRKAA1 protein]

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

phosphatase and tensin homolog

multiple interactions

ginsenoside Rg1 inhibits the reaction [Dibutyl Phthalate results in increased expression of PTEN protein]

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2]

PMID:22214447 PMID:29964319

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RAD51 recombinase

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of RAD51 mRNA]

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

ribosomal protein S6

increases phosphorylation

ginsenoside Rg1 results in increased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

regulatory associated protein of MTOR, complex 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [cobaltous chloride results in decreased activity of [MTOR protein binds to RAPTOR protein]]; ginsenoside Rg1 results in increased activity of [MTOR protein binds to RAPTOR protein]

NCBI chr10:104,878,487...105,176,986
Ensembl chr10:104,878,487...105,176,983

G

sirtuin 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of SIRT1 protein]

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SLC10A1 protein]

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier organic anion transporter family member 1B2

multiple interactions

SLCO1B2 protein binds to and results in increased transport of ginsenoside Rg1
SLCO1B3 protein binds to and results in increased transport of ginsenoside Rg1

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

superoxide dismutase 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in decreased expression of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

sulfotransferase family 2A member 1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of SULT2A1 protein]

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

trefoil factor 1

increases expression

ginsenoside Rg1 results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

tumor necrosis factor

multiple interactions

1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]]; ginsenoside Rg1 inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Chlorpyrifos results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased expression of TNF]; ginsenoside Rg1 inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]
ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in increased expression of TNF protein]; ginsenoside Rg1 inhibits the reaction [Oxygen deficiency results in increased expression of TNF protein]

PMID:22214447 PMID:29964319 PMID:30918470 PMID:32198087 PMID:36811218 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of TP53 mRNA]

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

UDP glucuronosyltransferase family 1 member A1

multiple interactions

ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 mRNA]; ginsenoside Rg1 inhibits the reaction [1-Naphthylisothiocyanate results in decreased expression of UGT1A1 protein]

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

X-ray repair cross complementing 1

multiple interactions

ginsenoside Rg1 promotes the reaction [Doxorubicin results in increased expression of XRCC1 mRNA]

NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701

ginsenoside Rg2

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 2

increases expression

ginsenoside Rg2 results in increased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

AKT serine/threonine kinase 1

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased phosphorylation of AKT1 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

BCL2 associated X, apoptosis regulator

multiple interactions

ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased expression of BAX protein]

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

ginsenoside Rg2 inhibits the reaction [APP protein modified form results in decreased expression of BCL2 protein]

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

beclin 2

multiple interactions

ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein]

NCBI chr13:87,842,980...87,892,410
Ensembl chr13:87,844,531...87,845,787

G

caspase 3

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of CASP3 protein]]; ginsenoside Rg2 inhibits the reaction [APP protein modified form results in increased activity of and results in increased cleavage of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

CREB regulated transcription coactivator 2

multiple interactions

[ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein

NCBI chr 2:175,709,603...175,719,768
Ensembl chr 2:175,709,644...175,719,763

G

glucose 6 phosphatase catalytic subunit 3

decreases expression
multiple interactions

ginsenoside Rg2 results in decreased expression of G6PC3 mRNA
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of G6PC3 mRNA]

NCBI chr10:87,146,987...87,151,223
Ensembl chr10:87,146,901...87,151,221

G

G protein-coupled receptor associated sorting protein 1

multiple interactions

ginsenoside Rg2 inhibits the reaction [BECN2 protein binds to GPRASP1 protein]

NCBI chr X:98,764,853...98,772,685
Ensembl chr X:98,709,841...98,772,851

G

glycogen synthase kinase 3 beta

increases phosphorylation
multiple interactions

ginsenoside Rg2 results in increased phosphorylation of GSK3B protein
[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of GSK3B protein]

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases expression

bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in increased expression of MAP1LC3B protein modified form]

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
increases expression
increases activity

[[ginsenoside Rg2 results in increased phosphorylation of GSK3B protein] co-treated with [ginsenoside Rg2 results in increased expression of NR0B2 mRNA]] results in decreased chemical synthesis of Glucose; [ginsenoside Rg2 results in increased activity of NR0B2 protein] which results in decreased activity of CRTC2 protein

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

phosphoenolpyruvate carboxykinase 1

multiple interactions
decreases expression

dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PCK1 mRNA]

NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191

G

PPARG coactivator 1 alpha

multiple interactions
decreases expression

dorsomorphin inhibits the reaction [ginsenoside Rg2 results in decreased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

sequestosome 1

multiple interactions
decreases expression

bafilomycin A1 promotes the reaction [ginsenoside Rg2 results in decreased expression of SQSTM1 protein]

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

serine/threonine kinase 11

increases phosphorylation
multiple interactions

ginsenoside Rg2 results in increased phosphorylation of STK11 protein
dorsomorphin inhibits the reaction [ginsenoside Rg2 results in increased phosphorylation of STK11 protein]

NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315

glycocholic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

affects transport
multiple interactions

ABCB11 protein affects the transport of Glycocholic Acid
[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCB11 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB11 mRNA

PMID:15791618 PMID:32152650 PMID:33819548

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCB4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily C member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC1 mRNA; Glycocholic Acid inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]

PMID:16101123 PMID:33819548

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC2 mRNA

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCC3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCC3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ABCC3 mRNA

PMID:32152650 PMID:33819548

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ABCC4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of ABCC4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ABCC4 mRNA

PMID:32152650 PMID:33819548

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily G member 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ABCG2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG2 mRNA

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 5

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG5 mRNA

NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563

G

ATP binding cassette subfamily G member 8

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ABCG8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

acyl-CoA synthetase long-chain family member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ACSL1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ACSL1 mRNA

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

adhesion G protein-coupled receptor G1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of ADGRG1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ADGRG1 mRNA

NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH1C mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

alcohol dehydrogenase 4 (class II), pi polypeptide

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH4 mRNA

NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591

G

alcohol dehydrogenase 6 (class V)

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ADH6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ADH6 mRNA

NCBI chr 2:226,903,208...226,934,564
Ensembl chr 2:226,903,250...226,934,534

G

aldo-keto reductase family 1 member A1

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1A1 mRNA

NCBI chr 5:130,092,945...130,130,277
Ensembl chr 5:130,092,732...130,113,674

G

aldo-keto reductase family 1, member D1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR1D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR1D1 mRNA

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldo-keto reductase family 7, member A2

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A2 mRNA

PMID:32152650 PMID:33819548

NCBI chr 5:151,552,375...151,560,914
Ensembl chr 5:151,552,343...151,560,909

G

aldo-keto reductase family 7 member A3

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of AKR7A3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of AKR7A3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AKR7A3 mRNA

PMID:32152650 PMID:33819548

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

albumin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ALB mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ALB mRNA

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, placental

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ALPP mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of ALPP mRNA

NCBI chr 9:87,765,846...87,768,606
Ensembl chr 9:87,765,860...87,768,606

G

adenosine monophosphate deaminase 3

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of AMPD3 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:164,885,320...164,929,887

G

aldehyde oxidase 1

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of AOX1 mRNA

NCBI chr 9:59,579,621...59,658,772
Ensembl chr 9:59,579,649...59,658,770

G

apolipoprotein A1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of APOA1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of APOA1 mRNA

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

activating transcription factor 4

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of ATF4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF4 mRNA

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

autophagy related 7

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of ATG7 mRNA

NCBI chr 4:147,718,663...147,925,656
Ensembl chr 4:147,718,752...147,925,593

G

ATPase phospholipid transporting 8B1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of ATP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of ATP8B1 mRNA

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

bile acid CoA:amino acid N-acyltransferase

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of BAAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of BAAT mRNA

NCBI chr 5:63,851,668...63,860,641
Ensembl chr 5:63,850,705...63,860,685

G

BTB domain and CNC homolog 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BACH1 mRNA

NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447

G

Bcl2-like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of BCL2L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of BCL2L1 mRNA

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

calcium voltage-gated channel auxiliary subunit alpha2delta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CACNA2D1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CACNA2D1 mRNA

NCBI chr 4:18,950,611...19,374,969
Ensembl chr 4:18,951,002...19,374,969

G

catalase

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CAT mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CAT mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CAT mRNA

PMID:32152650 PMID:33819548

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 1

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CBR1 mRNA

NCBI chr11:32,860,571...32,862,981
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393
Ensembl chr11:32,908,950...32,911,393

G

C-C motif chemokine receptor 2

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

chitinase 3 like 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CHI3L1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CHI3L1 mRNA

NCBI chr13:45,641,802...45,649,787
Ensembl chr13:45,641,802...45,649,787

G

colony stimulating factor 1

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CSF1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of CSF1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CSF1 mRNA

PMID:32152650 PMID:33819548

NCBI chr 2:195,377,215...195,396,608
Ensembl chr 2:195,377,215...195,411,704

G

catenin beta 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTNNB1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CTNNB1 mRNA

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cortactin

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of CTTN mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of CTTN mRNA

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

CYLD lysine 63 deubiquitinase

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of CYLD mRNA

NCBI chr19:18,310,632...18,373,696
Ensembl chr19:18,314,019...18,373,658

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of CYP1A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP1A1 mRNA

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP1A2 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP27A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP2B6 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2B6 mRNA

PMID:32152650 PMID:33819548

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C18 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP2C18 mRNA

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP2C19 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP2C19 mRNA

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP2C8 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP2C8 mRNA

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A4 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A4 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A4 mRNA

PMID:32152650 PMID:33819548

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP3A5 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP3A5 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of CYP7A1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP7A1 mRNA

PMID:32152650 PMID:33819548

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 7 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP7B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP7B1 mRNA

NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of CYP8B1 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DDIT3 mRNA

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DnaJ heat shock protein family (Hsp40) member B1

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB1 mRNA

NCBI chr19:24,522,731...24,526,419
Ensembl chr19:24,522,717...24,526,458

G

DnaJ heat shock protein family (Hsp40) member B11

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB11 mRNA

NCBI chr11:78,151,750...78,168,259
Ensembl chr11:78,150,429...78,180,407

G

DnaJ heat shock protein family (Hsp40) member B6

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB6 mRNA

NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJB9 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of DNAJB9 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJB9 mRNA

PMID:32152650 PMID:33819548

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C1

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC1 mRNA

NCBI chr17:80,955,209...81,112,025
Ensembl chr17:80,955,237...81,111,988

G

DnaJ heat shock protein family (Hsp40) member C10

multiple interactions

[Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in decreased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in increased expression of DNAJC10 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in increased expression of DNAJC10 mRNA; [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC10 mRNA

PMID:32152650 PMID:33819548

NCBI chr 3:65,232,031...65,272,732
Ensembl chr 3:65,232,697...65,272,719

G

DnaJ heat shock protein family (Hsp40) member C12

multiple interactions

[Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Atazanavir Sulfate] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Cyclosporine] results in increased expression of DNAJC12 mRNA; [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with nefazodone] results in increased expression of DNAJC12 mRNA

NCBI chr20:25,246,744...25,267,508
Ensembl chr20:25,223,144...25,267,521

G

DnaJ heat shock protein family (Hsp40) member C16

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression of DNAJC16 mRNA

NCBI chr 5:154,073,372...154,106,246
Ensembl chr 5:154,075,261...154,106,136

G

DnaJ heat shock protein family (Hsp40) member C18

multiple interactions

[Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in increased expression o